Navigation Links
Cancer Antigen 27.29

ProductsCancer Antigen 27.29
Company ARUP Laboratories
Item Cancer Antigen 27.29
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Breast Cancer Camera
2. Cancer Antigen 125 (Trademark of Fujirebio Diagnostic Inc.)
3. Vysis UroVysion Bladder Cancer Kit
4. Physicians Cancer Chemotherapy Drug Manual 2005
5. Pocket Guide to Colorectal Cancer Drugs and Treatment
6. Cochrane Reviews in Prostatic Diseases and Urologic Cancers
7. AFP (Liver Cancer)
8. Alpha Fetoprotein (Liver Cancer)
9. NMP22 Bladder Cancer ELISA Test Kit
10. BRAF V600E Detection of Colon Cancer (Unstable Tumors) by PCR
11. Cancer Antigen 125
The Vitatron Excellence + lead series are endocardial leads providing excellent handling and optimal pacing characteristics.
The family of Passive Plus DX passive-fixation leads features a 5 mm tip, designed to increase current density and pacing impedance, and a tine fixation, offering versatility and security in lead pla
Selute Picotip Atrial-J steroid eluting passive fixation lead
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
Medicine Products:
(Date:7/25/2008)...ormer McKesson Corporation Executive, Robert J. Re...ewswire/ -- Aethon Inc.,( http://www.aethon.com ),...ital supply chain logistics, today announced that ...Vice President -- Chief Financial Officer., Reill... Manager for,McKesson Corporation,s Specialty Phar...
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Fami... cancer treatment solutions at the 2008,American A... meeting,demonstrating how the joint forces of El...diation therapy planning and delivery solutions th...tter experience for,patients, as well as enhance c...
(Date:7/25/2008)... CARLSBAD, Calif., July 25 /PRNewswire/ -- AutoGe...egistration statement on Form S-1 with the,Securit...ed initial public,offering of shares of its common... offered, all of which are expected to be offered ... offering, have not yet been,determined., J.P. Mo...
(Date:7/25/2008)...turday can be toughest for those trying to drop po...ealthDay News) -- Anyone who has avoided Monday mo...ends are not a dieter,s friend. , Now, research...ts about weekends being their undoing: Most people...ing to lose weight. , "Weekend indulgences can ...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...established in the near future for those suffering...DS //. Health Minister Mary Harney said that he ...on of a Bill to address insurance difficulties fac...e diseases while administering blood and blood pro...
... Council is seeking various opinions on the issue ...ips with former patients //without fear of a ban. ...d to be extremely careful and remind them that the... be considered inappropriate. In a move that nul...
...epressant that had been linked to heart abnormalit...German researchers told a European fertility confe... found no increased risk and that women might have...ncies fearing that the drug could affect their bab...
...ed three doctors of the Indraprastha Apollo Hospit...d information //on the condition of Rahul Mahajan,...tion of suspected drug overdose. "We have summone...n," said Suman Nalwa, assistant commissioner of po...
Other Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2
(Date:7/23/2008)...- Sound Pharmaceuticals (SPI) has filed,an Investi... clinical,testing of a proprietary formulation of ... hearing loss or ototoxicity. The oral capsule,con...ced stage lung cancer,and head and neck cancer pat...marks the second development program for SPI to en...
(Date:7/23/2008)...rstCall/ -- Dendreon Corporation,(Nasdaq: DNDN ) ...ta,Monitoring Committee (IDMC) to review in Octobe...lating to the Company,s Phase 3 IMPACT (IMmunother...own as D9902B) clinical trial,of PROVENGE(R) (sipu...al,active cellular immunotherapy for the treatment...
(Date:7/22/2008)...s Development Initiative bring MJFF,s,current acti...nuary 20,2009, NEW YORK, July 22 /PRNewswire-USN...ry of transformative treatments and a cure for Par...r Parkinson,s Research has awarded,$2.7 million in... awards,were granted under MJFF,s Therapeutics Dev...
(Date:7/22/2008)...he Importance to Patients of Passing a ...OND, Va., July 22 /- Insmed...iologics and biopharmaceuticals, today,announced t...sent at a,Congressional briefing on Friday, July 2...blishing an approval pathway for follow-on,biologi...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 1Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 2Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 3Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 1Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 6Cardiva Medical Inc to Present at the Investment In Innovation 28In3 29 Medical Device Summit on June 18 2008 in San Francisco CA 3B Announces th 21891 1Cardiva Medical Inc to Present at the Investment In Innovation 28In3 29 Medical Device Summit on June 18 2008 in San Francisco CA 3B Announces th 21891 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 1PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 7
...NA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhe...day that interim Phase I data,has been published i...Proceedings (ASCO) (Abstract ID 32638). The data a... to evaluate the safety,tolerability, and pharmac...IT-101, in patients with inoperable or metastatic,...
... SAN FRANCISCO, Calif., June 01, 2007,/PRNewswire-...announced that the company will present data from ... the 12th Congress of the European,Hematology Asso...,Austria. , Presentations will include updated in...al of SNS-595 in acute leukemias, as,well as clini...
Other Medicine Technology:Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3